scholarly journals P3.13-22 Real World Study of Afatinib in First-Line or Re-Challenge Setting for Patients with EGFR Mutant Non-Small Cell Lung Cancer.

2018 ◽  
Vol 13 (10) ◽  
pp. S984
Author(s):  
H. Tanaka ◽  
K. Taima ◽  
M. Itoga ◽  
Y. Ishioka ◽  
K. Baba ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Real World ◽  
Small Cell ◽  
Small Cell Lung ◽  
First Line ◽  
Egfr Mutant

scholarly journals First‐Line Osimertinib in Patients with EGFR‐Mutant Advanced Non‐Small Cell Lung Cancer: Outcome and Safety in the Real World: FLOWER Study

2021 ◽  
Author(s):  
Martina Lorenzi ◽  
Alessandra Ferro ◽  
Fabiana Cecere ◽  
Daniela Scattolin ◽  
Alessandro Del Conte ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Real World ◽  
Small Cell ◽  
Small Cell Lung ◽  
First Line ◽  
The Real ◽  
Cancer Outcome ◽  
Egfr Mutant

scholarly journals Real-world study of afatinib in first-line or re-challenge settings for patients with EGFR mutant non-small cell lung cancer

2019 ◽  
Vol 36 (6) ◽  
Author(s):  
Hisashi Tanaka ◽  
Kageaki Taima ◽  
Masamichi Itoga ◽  
Yoshiko Ishioka ◽  
Keisuke Baba ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Real World ◽  
Small Cell ◽  
Small Cell Lung ◽  
First Line ◽  
Egfr Mutant

Real world study of afatinib in first-line or re-challenge setting for patients with EGFR mutant non-small cell lung cancer.

2018 ◽  
Vol 36 (15_suppl) ◽  
pp. e21173-e21173
Author(s):  
Hisashi Tanaka ◽  
Kageaki Taima ◽  
Masamichi Itoga ◽  
Yoshiko Ishioka ◽  
Keisuke Baba ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Real World ◽  
Small Cell ◽  
Small Cell Lung ◽  
First Line ◽  
Egfr Mutant
Sign in / Sign up

Export Citation Format

Share Document